Strivenn Thinking
Pull up a seat at our
digital campfire
where story, strategy,
and AI spark
new possibilities
for sharper brands
and smarter teams.
You Called It a Launch. Your Pipeline Disagrees.
By Jasmine Gruia-Gray
Closing the Gap Between Awareness and Conversion in RUO Life Sciences
Your product launched six weeks ago. The press release ran. The trade show booth drew 300 visitors. Your LinkedIn post earned 4,000 impressions and your VP sent a congratulatory Slack message.
And right now, your sales team is quietly telling you the pipeline is cold.
The CRM shows leads, but the leads are not moving. Your distributor partners are fielding technical questions they cannot answer. Researchers who stopped by the booth are not requesting evaluations. You did everything on the launch checklist.
You did not run a launch. You ran an announcement. There is a difference. And it is costing you pipeline you cannot recover.
An Announcement Gets Attention. A Launch Gets Pipeline.
The Romans understood this distinction with a precision we have largely lost.
Felicitas was the Roman goddess of success, good fortune, and favorable outcomes. She appeared on Roman coinage, stamped directly onto the face of transactions, because Romans understood that success was not wished into existence. It was earned. Her name gave Latin some of its most optimistic exports: felicity, felicitous, infelicitous, and felix, meaning favored, fortunate, or structurally happy.
Romans did not pray to Felicitas at the start of a campaign. They invoked her after building the infrastructure that made a favorable outcome probable. An army that marched without supply lines, siege equipment, and field intelligence was not courting Felicitas. It was hoping for a miracle. Romans were practical enough to know the difference between the two.
I've seen some Product Managers (PMs) announce products into markets with no conversion infrastructure behind the announcement, then attribute poor adoption to market timing, competitive pressure, or product-market fit. Then, they move onto the next product on the roadmap. Felicitas was not courted. She was never given the conditions to show up.
What the Confusion Actually Costs
A mid-sized instrument company announces a next-generation imaging system at a major conference. Three hundred researchers visit the booth. The press release gets picked up in numerous trade publications. The LinkedIn campaign generates 4,200 impressions. Nine months post-announcement, six units have been placed against a forecast of forty.
This is not a product problem. The imaging system performs. The problem is that the conversion infrastructure was absent at announcement: no validated imaging protocols for customer-relevant biological applications, no ROI framework a core facility director could use to justify capital expenditure, no field application specialist (FAS) coverage to support active evaluations. The market was curious. It had nowhere to go.
The PM could have more intentionally walked in the customer's shoes. Building a synthetic customer panel before launch gives you a proxy buyer to pressure-test conversion assets against, without waiting for the first real evaluation to expose the gaps. If your synthetic core facility director cannot justify the capital expenditure from your materials alone, neither can the real one.
In RUO life sciences, this pattern is particularly costly because the buyer is technically sophisticated and the sales cycle is long, especially with capital equipment. A researcher evaluating a new flow cytometry panel needs data validated in their specific cell types, not a spec sheet written for a general audience. A pharma procurement team considering a liquid handler needs a total cost of ownership model and a service coverage map. Awareness creates intent. Conversion requires proof. Most launch plans fund the former and starve the latter.
The Felicitas Framework: Four Pillars of Launch Readiness
Geoffrey Moore's Crossing the Chasm identifies the gap between early adopters and the early majority as the moment most product launches fail. Early adopters accept a promise. The early majority demands proof. The Felicitas Framework treats awareness and conversion as separate disciplines, funded separately, measured separately, and held accountable to separate outcomes.
Pillar 1: Awareness Assets (the announcement layer)
This is what most teams build well. Press releases, trade show presence, email campaigns, LinkedIn content, distributor briefings. These assets reach the market and create the initial signal. They are necessary. They are not Felicitas.
Measure them with awareness metrics: impressions, booth visits, email open rates, share of voice. Track them. Do not confuse movement in these numbers with a successful launch. You have created the conditions for curiosity. You have not yet given that curiosity somewhere to go.
Pillar 2: Conversion Assets (the proof layer)
This is where Felicitas lives. Conversion assets move a researcher from I heard about this to I am actively evaluating this. For a qPCR kit entering a competitive pharma screening workflow, this means head-to-head sensitivity data, a validated high-throughput protocol, and a technical note written for the assay development scientist (even if the author needs to remain anonymous) in that workflow, not the marketing team.
Before you commit budget to building these assets, test your asset list against a synthetic customer panel. The buyer persona who would never request an evaluation over a missing application note will tell you in one session what six months of pipeline silence cannot.
Conversion assets by product category
| Product type | Critical conversion asset | Common gap | Conversion metric |
|---|---|---|---|
| Assay kitsELISA, qPCR | Application notes with workflow-specific data | Gap Data validated only in standard conditions |
Evaluation-to-order rate |
| Flow cytometryPanels | Panel validation reports, spectral overlap data | Gap Validated internally, not in customer-relevant cell types |
Demo-to-trial conversion rate |
| Imaging systems | Representative image galleries, quantification benchmarks | Gap Demo images used instead of customer-relevant biology |
Qualified lead rate |
| Liquid handlers | Walkaway time calculations, integration protocols | Gap Performance data without real-world throughput context |
Time-to-close |
| Sequencers | Library prep comparisons, cost-per-sample models | Gap Spec sheet performance without comparative context |
Year-1 placement retention |
Felicitas shows up when you give the market a reason to move.
Measure conversion assets with conversion metrics: qualified lead rate, evaluation-to-order conversion, demo request volume. When these numbers are weak, the problem is almost always in the proof layer (Pillar 2), not the announcement layer (Pillar 1).
Pillar 3: Sales Readiness (the delivery layer)
A conversion asset sitting in a shared folder that no one has read is not a conversion asset. Sales readiness means your FASes can demonstrate the product under customer-relevant conditions today. Your inside sales team can handle the first ten objections without escalating. Your distributor partners were trained before the announcement went live, not two weeks after.
What great looks like: a PM who allocates a meaningful share of the launch budget to conversion assets and FAS training walks her team into every customer meeting with a validated protocol and a competitive comparison tailored to that customer's specific workflow. Pipeline moves. Felicitas shows up.
Measure with time-to-close, first-call resolution rate, and escalation frequency in the first 90 days post-announcement.
Pillar 4: Customer Infrastructure (the retention layer)
Conversion does not end at purchase. In RUO life sciences, year-one retention and reorder rate are the real indicators of launch health. Customer infrastructure means onboarding kits, application support coverage, reorder trigger programs, and a customer success touchpoint within 90 days of first placement.
A sequencer placed without a scheduled first-quarter application review is a sequencer at risk of competitive displacement at year-two renewal. A successful launch requires the full conversion cycle to complete, not just the first transaction.
The Felicitas Audit: Five Questions Before You Announce
Run this before any announcement goes live. Test these questions against your synthetic customer panel. If you cannot answer yes to all five, you are only announcement ready, but not conversion ready.
- Conversion asset test: Can a technically sophisticated buyer self-qualify without speaking to your team?
- Sales readiness test: Can every field team member demonstrate in a customer-relevant workflow today?
- Pipeline infrastructure test: Is there a documented, tested path from first contact to closed order?
- Channel readiness test: Does every distributor partner have materials to answer the top five technical objections?
- Retention infrastructure test: Is there a customer success touchpoint planned within 90 days of first placement?
Build the Infrastructure. Then Announce.
The PMs who earn Felicitas do not announce and hope. They build first: the validated application data, the trained field team, the customer success touchpoint, the ROI model the core facility director actually needs. Then they announce into a pipeline that is already ready to move.
The teams that get this right separate awareness budgets from conversion budgets, hold them accountable to distinct metrics, and measure launch health by pipeline velocity rather than impression count.
If you own upstream but not launch, this framework is your briefing document for the Marketing Manager who does.
The announcement tells the market you exist. Felicitas shows up when you give the market a reason to move.
Run your announcement plan and your launch plan in parallel. Build conversion infrastructure before you press send. Run the Felicitas Audit and be honest about what you find. And yes, a synthetic customer panel is invaluable.
Q: My leadership measures launch success by press coverage and trade show leads. How do I reframe the conversation? ▼
This is a genuine organizational challenge and the frustration is warranted. Connect awareness metrics to conversion metrics in a single dashboard so leadership sees the full funnel, not just the top. Start by calculating what a qualified lead costs when conversion assets are missing: if your trade show generates 300 leads and you convert 2%, that is 6 customers at a significant acquisition cost per head. Present the Felicitas Audit results alongside your awareness plan at the next launch review. Leadership changes the metric when the gap between investment and return is visible in one table, not scattered across three spreadsheets and a pipeline report they have not opened.
Q: Our conversion assets are still in development when the launch window opens. Delay or announce anyway? ▼
There is no clean answer, but there is a clear test: ask whether your conversion rate will be materially worse without the assets in place. If you are announcing to a technically sophisticated buyer who needs application data to evaluate, announcing without it does not accelerate the pipeline. It creates a holding pattern that burns goodwill and generates leads your team cannot convert. A phased announcement, routing interest toward a beta program or waitlist while assets are completed, is often more effective than a full launch with incomplete conversion infrastructure. Phased is not a compromise. It is the smarter play.
Q: How do I get sales on board when they are already fielding inquiries and pushing to close?▼
Acknowledge the tension directly. Sales teams are incentivized to close now, not wait for materials that may never arrive on time. The most effective approach is to involve the field team in building Pillar 2 assets rather than asking them to pause. The application note your FASes helped write is the one they will actually use in front of a customer. Give them co-authorship and a concrete delivery timeline, not a promise.
